Aduhelm (aducanumab-avwa) is a prescription drug that’s used to treat Alzheimer’s disease. The drug comes as a liquid solution for intravenous (IV) infusion by a healthcare professional. It’s usually ...

Biogen is cutting ties with Aduhelm, the Alzheimer’s disease drug that won a landmark but controversial regulatory approval and then became a commercial flop. Development and commercialization of ...

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history ...

There has been considerable controversy surrounding Aduhelm since the Food and Drug Administration (FDA) granted the drug accelerated approval in 2021. The accelerated approval of Aduhelm has been ...